NEW YORK (GenomeWeb News) – Investment bank Cantor Fitzgerald today initiated coverage of Cancer Genetics with a Buy rating and a $21 price target on its shares.

In a research note, analyst Sung Ji Nam said that challenges await companies developing and commercializing genomic tests, but Rutherford, NJ-based Cancer Genetics has strengths in leveraging clinical development collaborations with leading healthcare partners. Additionally, Nam said, the company has one of the most comprehensive sets of diagnostic services targeting cancer types.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

University of California, San Diego, researchers have developed a gene drive to control a fruit-destroying fly.

A new study of a β-thalassemia gene therapy appears promising, according to NPR.

Futurism writes that gene doping could be the next generation of cheating in sports.

In Nature this week: hair color genes, hybridization between 13-year and 17-year cicadas, and more.

May
15
Sponsored by
Tecan

This webinar will discuss how an algorithm-driven synthetic biology system can enable engineering of biological systems for a range of applications.

Jun
20
Sponsored by
PerkinElmer

In this webinar, Michael Quail of the R&D Sequencing team at the Wellcome Trust Sanger Institute will provide an expert perspective on library prep for next-generation sequencing.

Jun
28
Sponsored by
PerkinElmer

This webinar will review a standardized, high-throughput, and fully automated library prep protocol for human metagenomic analysis.